WordPress database error: [Error writing file '/tmp/MYXlmgH6' (Errcode: 28 - No space left on device)]
SELECT t.*, tt.*, tr.object_id FROM wp_terms AS t INNER JOIN wp_term_taxonomy AS tt ON t.term_id = tt.term_id INNER JOIN wp_term_relationships AS tr ON tr.term_taxonomy_id = tt.term_taxonomy_id WHERE tt.taxonomy IN ('category', 'post_tag', 'post_format') AND tr.object_id IN (337948, 350944, 352696, 352751, 357144, 360729, 364381, 371627, 379657, 380738, 389552, 399144, 401874, 402106, 405419, 406023, 408337, 413117, 422203, 428851) ORDER BY t.name ASC

Formulation Archives - Newsemia

Tag : Formulation

Uncategorized

La Commission européenne accorde une autorisation de mise sur le marché pour la première formulation sous-cutanée au monde d’infliximab, Remsima® SC, pour cinq indications additionnelles dont son utilisation dans le traitement de la maladie …

Newsemia
INCHEON, Corée du Sud–(BUSINESS WIRE)–  La Commission européenne accorde une autorisation de mise sur le marché pour la première formulation sous-cutanée au monde d’infliximab, Remsima®...
Uncategorized

European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima® SC, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis

Newsemia
INCHEON, South Korea–(BUSINESS WIRE)–Celltrion Healthcare today announced that the European Commission (EC) has granted marketing authorisation for Remsima® (infliximab, CT-P13) subcutaneous (SC) formulation for the...
Uncategorized

Subcutaneous Formulation of DARZALEX®▼(Daratumumab) Combination Resulted in Deep and Rapid Haematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

Newsemia
BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomised Phase 3 study investigating the subcutaneous (SC) formulation...
Uncategorized

Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension

Newsemia
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, announced that...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World